Kakkar Aanchal, Ashraf Subiyathul Farah, Rathor Amber, Adhya Amit Kumar, Mani Suresh, Sikka Kapil, Jain Deepali
From the Department of Pathology (Kakkar, Ashraf, Rathor, Jain), All India Institute of Medical Sciences, New Delhi, India.
The Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, India (Adhya).
Arch Pathol Lab Med. 2022 Sep 1;146(9):1122-1130. doi: 10.5858/arpa.2021-0001-OA.
CONTEXT.—: Molecular analysis of poorly differentiated/undifferentiated sinonasal neoplasms has resulted in identification of a growing number of genetically defined tumors. SMARCA4-deficient sinonasal carcinoma is one such recently described entity that emerged from within sinonasal undifferentiated carcinoma (SNUC), neuroendocrine carcinoma (NEC), and teratocarcinosarcoma (TCS).
OBJECTIVE.—: To identify SMARCA4-deficient sinonasal carcinomas from a large institutional cohort of poorly differentiated/undifferentiated carcinomas and evaluate their clinicopathologic features.
DESIGN.—: SMARCA4/BRG1 immunohistochemistry was performed on all tumors diagnosed as SNUC, poorly differentiated carcinoma, NEC, and TCS during a 12-year period. SMARCA2/BRM and INSM1 immunostaining was performed in SMARCA4-deficient cases.
RESULTS.—: Twelve SMARCA4-deficient sinonasal carcinomas were identified among 299 cases. Morphologically, 5 cases were large cell NEC, 2 cases were small cell NEC, and 5 were TCS. SMARCA4 loss was diffuse and complete in 10 cases, while 2 cases showed focal retention. Most cases showed diffuse cytokeratin staining accompanied by weak, usually focal staining for chromogranin and synaptophysin. INSM-1 showed negativity in most cases. All cases showed retained SMARCA2 expression. IDH1/2 mutation was absent in all cases analyzed. Four of 7 patients died of disease, and aggressive multimodality treatment provided better outcome.
CONCLUSIONS.—: SMARCA4-deficient sinonasal carcinomas are morphologically akin to sinonasal poorly differentiated NECs and TCS, display cytokeratin positivity and only focal staining for neuroendocrine markers, and have aggressive biological behavior. Inclusion of SMARCA4 in the immunohistochemical panel for diagnostic workup of all sinonasal NEC and TCS phenotypes will facilitate their early recognition. Comprehensive germline and somatic mutational analyses of these tumors are necessary for further insights into their molecular pathogenesis.
对低分化/未分化鼻窦肿瘤的分子分析已鉴定出越来越多基因明确的肿瘤。SMARCA4缺陷型鼻窦癌就是最近描述的一种实体肿瘤,它源自鼻窦未分化癌(SNUC)、神经内分泌癌(NEC)和畸胎癌肉瘤(TCS)。
从大量低分化/未分化癌的机构队列中识别出SMARCA4缺陷型鼻窦癌,并评估其临床病理特征。
对12年间诊断为SNUC、低分化癌、NEC和TCS的所有肿瘤进行SMARCA4/BRG1免疫组织化学检测。对SMARCA4缺陷病例进行SMARCA2/BRM和INSM1免疫染色。
在299例病例中鉴定出12例SMARCA4缺陷型鼻窦癌。形态学上,5例为大细胞NEC,2例为小细胞NEC,5例为TCS。10例SMARCA4缺失为弥漫性且完全缺失,而2例显示局灶性保留。大多数病例显示弥漫性细胞角蛋白染色,伴有嗜铬粒蛋白和突触素的弱阳性,通常为局灶性染色。大多数病例中INSM-1呈阴性。所有病例均显示SMARCA2表达保留。所有分析病例均未检测到IDH1/2突变。7例患者中有4例死于疾病,积极的多模式治疗提供了更好的结果。
SMARCA4缺陷型鼻窦癌在形态学上类似于鼻窦低分化NEC和TCS,显示细胞角蛋白阳性,神经内分泌标志物仅局灶性染色,且具有侵袭性生物学行为。在所有鼻窦NEC和TCS表型的诊断检查免疫组织化学检测中加入SMARCA4将有助于早期识别。对这些肿瘤进行全面的种系和体细胞突变分析对于进一步了解其分子发病机制是必要的。